| EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
| RS60131B1 (en) | 2013-07-05 | 2020-05-29 | Genmab As | Humanized or chimeric cd3 antibodies |
| RS60443B1 (en) | 2013-12-17 | 2020-07-31 | Genentech Inc | Anti-cd3 antibodies and methods of use |
| CR20170095A (en) | 2014-09-12 | 2017-07-19 | Genentech Inc | ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS RECIPROCAL REFERENCES WITH RELATED APPLICATIONS |
| EP3310814B1 (en) | 2015-06-16 | 2023-08-02 | F. Hoffmann-La Roche AG | Humanized and affinity matured antibodies to fcrh5 and methods of use |
| EP3310378B1 (en) | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| JP2018526972A (en) | 2015-06-16 | 2018-09-20 | ジェネンテック， インコーポレイテッド | Anti-CD3 antibody and method of use |
| AU2016293073B2 (en) | 2015-07-15 | 2022-12-22 | Genmab A/S | Humanized or chimeric CD3 antibodies |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide assembly and methods of making and using the same |
| AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
| EP3252078A1 (en)* | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| WO2018220099A1 (en)* | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| US11125751B2 (en) | 2016-09-30 | 2021-09-21 | Centre National De La Recherche Scientifique | Method for isolating HIV reservoir cells expressing CD32a cell marker |
| TWI791471B (en)* | 2016-11-15 | 2023-02-11 | 美商建南德克公司 | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| EP3559034B1 (en)* | 2016-12-20 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
| EP3661555B1 (en) | 2017-08-01 | 2025-04-16 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| KR102758346B1 (en) | 2017-08-04 | 2025-01-24 | 젠맵 에이/에스 | Binding agent that binds to PD-L1 and CD137 and uses thereof |
| WO2019034580A1 (en)* | 2017-08-14 | 2019-02-21 | Morphosys Ag | Humanized antibodies for cd3 |
| CN107501412A (en)* | 2017-10-11 | 2017-12-22 | 深圳精准医疗科技有限公司 | Saltant type bispecific antibody and its application |
| CA3089287A1 (en) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
| SG11202006583VA (en) | 2018-02-09 | 2020-08-28 | Genmab As | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
| WO2019175658A1 (en)* | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
| EP3569617A1 (en)* | 2018-05-18 | 2019-11-20 | Trion Research GmbH | Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases |
| CN110540593B (en)* | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | Novel anti-CD 3/anti-CD 20 bispecific antibodies |
| US12129298B2 (en)* | 2018-06-21 | 2024-10-29 | Daiichi Sankyo Company, Limited | Compositions including CD3 antigen binding fragments and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109836502B (en)* | 2018-11-12 | 2021-09-07 | 浙江大学 | A kind of bispecific antibody and its application |
| WO2020168555A1 (en)* | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | Cd3 antigen binding fragment and application thereof |
| CN113811770B (en)* | 2019-05-13 | 2024-06-28 | 豪夫迈·罗氏有限公司 | Suppression of interference in pharmacokinetic immunoassays |
| CN110551221B (en)* | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | Bispecific antibody and preparation method and application thereof |
| MX2022001721A (en)* | 2019-08-15 | 2022-03-11 | Genmab As | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES DIRECTED AGAINST CD3 AND CD20 AND THEIR USES. |
| CN111100204B (en)* | 2019-11-26 | 2022-03-11 | 山东立菲生物产业有限公司 | Antibody targeting CD20, preparation method and application thereof |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| WO2021144315A1 (en)* | 2020-01-13 | 2021-07-22 | Synaffix B.V. | Conjugates of antibodies an immune cell engagers |
| CN113402612A (en)* | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof |
| TW202200624A (en) | 2020-03-18 | 2022-01-01 | 丹麥商珍美寶股份有限公司 | Antibodies |
| US20230227570A1 (en) | 2020-05-08 | 2023-07-20 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| US10981996B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en)* | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| CN112062855B (en)* | 2020-08-26 | 2024-08-30 | 北京天诺健成医药科技有限公司 | Development and application of drug therapeutic agent containing adapter |
| MX2023002542A (en) | 2020-09-10 | 2023-03-15 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma. |
| CA3190349A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
| BR112023004321A2 (en) | 2020-09-10 | 2023-04-04 | Genmab As | METHOD FOR TREATMENT OF DIFFUSED GRAND B-CELL LYMPHOMA IN A HUMAN SUBJECT |
| IL301086A (en) | 2020-09-10 | 2023-05-01 | Genmab As | Bispecific antibody against CD3 and CD20 in combination therapy for the treatment of follicular lymphoma |
| US20230312759A1 (en)* | 2020-09-10 | 2023-10-05 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| AU2021341509A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma |
| US12351643B2 (en) | 2020-11-04 | 2025-07-08 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| CN114656562B (en)* | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | Antibodies that bind human and monkey CD3 and uses thereof |
| US12274747B2 (en) | 2021-01-28 | 2025-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| US20240139322A1 (en)* | 2021-03-10 | 2024-05-02 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods to reduce therapeutic t cell toxicity |
| IL305636A (en)* | 2021-03-12 | 2023-11-01 | Genmab As | Non-activating antibody variants |
| CN117321078A (en) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | Administration for combination therapy with anti-CD 20/anti-CD 3 bispecific antibody and anti-CD 79B antibody drug conjugates |
| WO2022241235A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| US20230241211A1 (en) | 2022-01-28 | 2023-08-03 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| US20230303693A1 (en) | 2022-01-28 | 2023-09-28 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| IL316002A (en) | 2022-04-11 | 2024-11-01 | Regeneron Pharma | Universal tumor cell killing compositions and methods |
| WO2023198839A2 (en) | 2022-04-13 | 2023-10-19 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| TW202519266A (en) | 2022-04-13 | 2025-05-16 | 美商建南德克公司 | Pharmaceutical compositions of mosunetuzumab and methods of use |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| AU2023398887A1 (en)* | 2022-12-14 | 2025-06-26 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
| WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| WO2024206884A1 (en) | 2023-03-31 | 2024-10-03 | AbelZeta Inc. | Bispecific chimeric antigen receptors targeting cd20 and bcma |
| AU2024255174A1 (en) | 2023-04-13 | 2025-10-09 | Genmab A/S | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 |
| WO2024236035A1 (en) | 2023-05-15 | 2024-11-21 | Genmab A/S | Methods of treating cd20 expressing b-cell cancers |
| US20240400685A1 (en) | 2023-05-15 | 2024-12-05 | Genmab A/S | Highly purified epcoritamab compositions |
| WO2025064890A1 (en)* | 2023-09-20 | 2025-03-27 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof |
| WO2025109119A1 (en)* | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |